BR112018017307A2 - molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus - Google Patents
molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírusInfo
- Publication number
- BR112018017307A2 BR112018017307A2 BR112018017307A BR112018017307A BR112018017307A2 BR 112018017307 A2 BR112018017307 A2 BR 112018017307A2 BR 112018017307 A BR112018017307 A BR 112018017307A BR 112018017307 A BR112018017307 A BR 112018017307A BR 112018017307 A2 BR112018017307 A2 BR 112018017307A2
- Authority
- BR
- Brazil
- Prior art keywords
- zika virus
- immune response
- methods
- nucleic acid
- zika
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662300030P | 2016-02-25 | 2016-02-25 | |
| US201662305183P | 2016-03-08 | 2016-03-08 | |
| US201662396742P | 2016-09-19 | 2016-09-19 | |
| US201662417100P | 2016-11-03 | 2016-11-03 | |
| US201762462249P | 2017-02-22 | 2017-02-22 | |
| PCT/US2017/019407 WO2017147458A1 (en) | 2016-02-25 | 2017-02-24 | Novel vaccines against zika virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018017307A2 true BR112018017307A2 (pt) | 2019-01-08 |
Family
ID=59685658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018017307A BR112018017307A2 (pt) | 2016-02-25 | 2017-02-24 | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11648303B2 (https=) |
| EP (1) | EP3419660A4 (https=) |
| JP (3) | JP7012365B2 (https=) |
| KR (1) | KR20190003471A (https=) |
| CN (2) | CN115927399A (https=) |
| AU (3) | AU2017222644B2 (https=) |
| BR (1) | BR112018017307A2 (https=) |
| CA (1) | CA3015792A1 (https=) |
| MX (2) | MX2018010291A (https=) |
| WO (1) | WO2017147458A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| AU2017222644B2 (en) | 2016-02-25 | 2021-07-29 | The Trustees Of The University Of Pennsylvania | Novel vaccines against Zika virus |
| CA3040123A1 (en) * | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
| US11806393B2 (en) * | 2017-02-10 | 2023-11-07 | La Jolla Institute For Allergy And Immunology | Flavivirus peptide sequences, epitopes, and methods and uses thereof |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| KR20200117981A (ko) | 2017-11-03 | 2020-10-14 | 다케다 백신즈 인코포레이티드 | 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들 |
| MX2020005554A (es) | 2017-11-30 | 2020-10-12 | Takeda Vaccines Inc | Vacunas y composiciones inmunogenas para zika y metodos para usarlas. |
| US11491217B2 (en) | 2017-12-06 | 2022-11-08 | Emory University | Chimeric viruses encoding mutant zika virus envelope glycoproteins |
| EP3826672A4 (en) | 2018-07-23 | 2022-04-20 | The University of Adelaide | VACCINE AGAINST THE ZIKA VIRUS |
| WO2020092564A1 (en) * | 2018-10-31 | 2020-05-07 | Icahn School Of Medicine At Mount Sinai | Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| US20250269010A1 (en) * | 2021-02-05 | 2025-08-28 | St Pharm Co., Ltd. | Novel nucleic acid molecule |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU774045B2 (en) * | 1998-09-02 | 2004-06-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Dengue viruses that are replication defective in mosquitos for use as vaccines |
| EP2026839A4 (en) * | 2005-12-14 | 2009-04-01 | Univ Oklahoma | RNA VIRUS VACCINE AND METHODS |
| KR101686942B1 (ko) | 2008-01-11 | 2016-12-28 | 이노비오 파마수티컬즈, 인크. | 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신 |
| EP2358733B1 (en) * | 2008-11-17 | 2015-07-08 | Inovio Pharmaceuticals, Inc. | Antigens that elicit immune response against flavivirus and methods of using same |
| WO2011032179A1 (en) * | 2009-09-14 | 2011-03-17 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
| KR102138780B1 (ko) | 2009-11-02 | 2020-07-29 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 구제역 바이러스(ｆｍｄｖ) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신 |
| US8691961B1 (en) | 2009-11-09 | 2014-04-08 | Integral Molecular, Inc. | Flavivirus reporter virus and methods of making and using the same |
| WO2011115583A1 (en) | 2010-03-19 | 2011-09-22 | National University Of Singapore | A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens |
| EP2550292B1 (en) * | 2010-03-24 | 2017-11-22 | Research Development Foundation | Flavivirus host range mutations and uses thereof |
| CA2819552C (en) * | 2010-12-09 | 2023-09-26 | Institut Pasteur | Mgmt-based method for obtaining high yield of recombinant protein expression |
| EA033467B1 (ru) | 2011-01-31 | 2019-10-31 | Univ Pennsylvania | Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение |
| BR112014013745B1 (pt) | 2011-12-09 | 2022-06-14 | Institut Pasteur | Método de teste in vitro, kit de detecção e seu uso, método in vitro de diagnóstico, método de fabricação de kit, e teste de imunosseleção multiplex |
| WO2014144786A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of dengue virus |
| EP3322441A4 (en) | 2015-07-16 | 2018-12-19 | Bharat Biotech International Limited | Vaccine compositions |
| MA42502A (fr) * | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| WO2017070624A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| SG10201913630YA (en) * | 2016-02-17 | 2020-03-30 | Curevac Ag | Zika virus vaccine |
| AU2017222644B2 (en) * | 2016-02-25 | 2021-07-29 | The Trustees Of The University Of Pennsylvania | Novel vaccines against Zika virus |
| MX2019000725A (es) * | 2016-07-18 | 2019-07-04 | Variation Biotechnologies Inc | Composiciones de vacuna para tratamiento de virus zika. |
| BR112019005378A2 (pt) * | 2016-09-19 | 2019-08-27 | The Trustees Of The University Of Pennsylvania | molécula de ácido nucleico, composição, e, métodos para prevenir ou tratar uma doença e para induzir uma resposta imune |
| CA3049991A1 (en) * | 2017-01-11 | 2018-07-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an immune response against zika virus |
| EP3412307A1 (en) * | 2017-06-07 | 2018-12-12 | Institut Pasteur | Recombinant measles virus expressing zika virus proteins and their applications |
-
2017
- 2017-02-24 AU AU2017222644A patent/AU2017222644B2/en active Active
- 2017-02-24 US US16/078,270 patent/US11648303B2/en active Active
- 2017-02-24 KR KR1020187027172A patent/KR20190003471A/ko active Pending
- 2017-02-24 CA CA3015792A patent/CA3015792A1/en active Pending
- 2017-02-24 CN CN202211273088.5A patent/CN115927399A/zh active Pending
- 2017-02-24 JP JP2018544819A patent/JP7012365B2/ja active Active
- 2017-02-24 BR BR112018017307A patent/BR112018017307A2/pt unknown
- 2017-02-24 WO PCT/US2017/019407 patent/WO2017147458A1/en not_active Ceased
- 2017-02-24 MX MX2018010291A patent/MX2018010291A/es unknown
- 2017-02-24 EP EP17757325.0A patent/EP3419660A4/en active Pending
- 2017-02-24 CN CN201780017976.1A patent/CN109152826B/zh active Active
-
2018
- 2018-08-24 MX MX2023006203A patent/MX2023006203A/es unknown
-
2021
- 2021-10-29 AU AU2021258056A patent/AU2021258056B2/en active Active
- 2021-11-22 JP JP2021189383A patent/JP7555325B2/ja active Active
-
2023
- 2023-05-16 US US18/318,061 patent/US12419945B2/en active Active
-
2024
- 2024-04-30 JP JP2024073806A patent/JP2024096281A/ja active Pending
- 2024-07-04 AU AU2024204641A patent/AU2024204641A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190003471A (ko) | 2019-01-09 |
| CN109152826B (zh) | 2022-11-04 |
| JP2024096281A (ja) | 2024-07-12 |
| JP2022023241A (ja) | 2022-02-07 |
| AU2024204641A1 (en) | 2024-07-25 |
| WO2017147458A1 (en) | 2017-08-31 |
| MX2023006203A (es) | 2023-06-12 |
| CN109152826A (zh) | 2019-01-04 |
| JP7012365B2 (ja) | 2022-03-04 |
| MX2018010291A (es) | 2019-06-06 |
| AU2021258056B2 (en) | 2024-04-04 |
| AU2017222644A1 (en) | 2018-09-13 |
| US20240115689A1 (en) | 2024-04-11 |
| US12419945B2 (en) | 2025-09-23 |
| JP2019506175A (ja) | 2019-03-07 |
| US20210315987A1 (en) | 2021-10-14 |
| AU2017222644B2 (en) | 2021-07-29 |
| US11648303B2 (en) | 2023-05-16 |
| JP7555325B2 (ja) | 2024-09-24 |
| EP3419660A4 (en) | 2019-11-06 |
| EP3419660A1 (en) | 2019-01-02 |
| CN115927399A (zh) | 2023-04-07 |
| CA3015792A1 (en) | 2017-08-31 |
| AU2021258056A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| CL2021000636A1 (es) | Vacuna contra el virus de la peste porcina africana | |
| CL2019000704A1 (es) | Vectores de adenovirus canino. | |
| BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
| BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
| BR112018012873A2 (pt) | vacina de vírus zika | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| MX392857B (es) | Nuevos virus de tilapia y sus usos. | |
| BR112013020070A8 (pt) | moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas | |
| BRPI1007721B1 (pt) | composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66 | |
| BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
| BR112015000585A8 (pt) | método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante | |
| BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
| BR112018016912A2 (pt) | novo antígeno para uso na vacina contra malária | |
| BR112016026651A2 (pt) | evolução de vesículas semelhantes a vírus de alta titulação para aplicações de vacina | |
| BR112014023414A2 (pt) | vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos | |
| BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
| CL2012000783A1 (es) | Proceso para mejorar la eficacia de proteccion metodo para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de dna y virus quimericos 17d; composicion vacunal que comprende vacunas de dna contra los cuatro serotipos del virus dengue y virus quimericos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína e. | |
| EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением | |
| BR112013013016A2 (pt) | modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14 | |
| BR112014023283A8 (pt) | Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza | |
| BR112017004356A2 (pt) | antígenos de streptococcus agalactiae associados a cepas virulentais em peixes | |
| AR093530A1 (es) | Adyuvante de vacunacion, preparacion, y vacunas que lo contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |